Here’s a simplified version of the text:
There have been some important updates from major biotech companies like Biogen and Novartis, as well as news from Resalis Therapeutics and Moderna.
Biogen has made significant leadership changes. They appointed Daniel Quirk as their new chief medical officer and announced that their chief financial officer, Michael McDonnell, will retire at the end of February. Robin Kramer, Biogen’s current top accountant, will take over McDonnell’s role.
Novartis has reduced the value of MorphoSys, a business they bought earlier this year, by $800 million. This is because the expected approval timeline for MorphoSys’ drug, pelabresib, has been delayed.
Sanofi has invested in Resalis Therapeutics, an Italian biotech company. Resalis is developing a new type of RNA-based medicine to treat metabolic diseases like obesity. They are preparing for early trials of this medicine.
Moderna and Merck & Co. are starting a new Phase 3 trial for their personalized cancer vaccine. This trial will test the vaccine with another drug, Keytruda, for early-stage lung cancer. They have already been testing this vaccine for melanoma and lung cancer, with results expected in 2029 and 2030.